Olario-F Tablet MD is a combination pharmaceutical formulation containing Fluoxetine 20mg and Olanzapine 5mg, indicated for the treatment of major depressive disorder with psychotic features, treatment-resistant depression, and certain bipolar disorders. Fluoxetine, a selective serotonin reuptake inhibitor (SSRI), enhances serotonergic neurotransmission by inhibiting serotonin reuptake in the central nervous system, thereby alleviating depressive symptoms. Olanzapine, an atypical antipsychotic, acts by antagonizing dopamine D2 and serotonin 5-HT2A receptors, contributing to the management of psychotic symptoms and mood stabilization. The synergistic effect of these agents addresses both mood and psychotic symptoms, improving overall therapeutic outcomes. Olario-F Tablet MD should be administered under strict medical supervision with dosage adjustments tailored to individual patient response and tolerability. Common adverse effects may include sedation, weight gain, dry mouth, dizziness, and gastrointestinal disturbances. Caution is advised in patients with a history of cardiovascular disease, diabetes, or seizure disorders. Regular monitoring of metabolic parameters, blood glucose, and lipid profile is recommended during prolonged therapy. This combination is contraindicated in patients with hypersensitivity to either component, and abrupt discontinuation should be avoided to prevent withdrawal symptoms. Olario-F Tablet MD offers an effective pharmacological option for complex depressive and psychotic conditions requiring combined serotonergic and antipsychotic intervention.